Cardioxyl Pharmaceuticals
Prodrugs for ADHF

Cyteir is a pharmaceutical company developing small molecule inhibitors against DNA repair pathways for oncology and auto-immune applications. Cyteir’s underlying platform is based on the scientific paradigm of ‘synthetic lethality’. Due to certain genomic changes that support increased growth, tumor cells become more susceptible to inhibition of certain complementary pathways. Cyteir’s lead program is targeting cancel cells that overexpress AID protein which makes them increasingly sensitive to inhibition of homologous recombination. Acquired by: Bristol-Myers Squibb


University
Johns Hopkins University
Sector
Life Science
Status
Exited
Initial Investment Stage
Early
View Website